Stephens Investment Management Group LLC Has $45.89 Million Holdings in DexCom, Inc. (NASDAQ:DXCM)

Stephens Investment Management Group LLC raised its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 2.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 684,485 shares of the medical device company's stock after buying an additional 19,279 shares during the period. Stephens Investment Management Group LLC owned approximately 0.17% of DexCom worth $45,888,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Migdal Insurance & Financial Holdings Ltd. purchased a new position in DexCom in the second quarter valued at about $25,000. Sachetta LLC increased its stake in shares of DexCom by 255.2% during the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company's stock worth $27,000 after purchasing an additional 171 shares in the last quarter. Crewe Advisors LLC purchased a new position in shares of DexCom during the 1st quarter worth approximately $29,000. Riverview Trust Co increased its stake in shares of DexCom by 100.4% during the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company's stock worth $31,000 after purchasing an additional 232 shares in the last quarter. Finally, DT Investment Partners LLC increased its stake in shares of DexCom by 492.2% during the 2nd quarter. DT Investment Partners LLC now owns 379 shares of the medical device company's stock worth $43,000 after purchasing an additional 315 shares in the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have recently weighed in on DXCM. Piper Sandler reissued an "overweight" rating and set a $90.00 price objective on shares of DexCom in a research note on Monday, August 26th. UBS Group decreased their target price on shares of DexCom from $163.00 to $95.00 and set a "buy" rating on the stock in a research report on Friday, July 26th. Barclays decreased their price target on shares of DexCom from $138.00 to $113.00 and set an "equal weight" rating on the stock in a report on Monday, July 29th. Raymond James decreased their price target on shares of DexCom from $115.00 to $99.00 and set a "strong-buy" rating on the stock in a report on Friday, October 25th. Finally, Leerink Partners decreased their price target on shares of DexCom from $90.00 to $87.00 and set an "outperform" rating on the stock in a report on Friday, October 25th. Six equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $104.59.

Insider Activity

In other news, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the transaction, the chief operating officer now directly owns 264,915 shares of the company's stock, valued at approximately $18,318,872.25. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other DexCom news, COO Jacob Steven Leach sold 746 shares of the business's stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the transaction, the chief operating officer now directly owns 264,915 shares of the company's stock, valued at $18,318,872.25. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Sadie Stern sold 426 shares of the business's stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the transaction, the executive vice president now directly owns 75,451 shares of the company's stock, valued at $5,217,436.65. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.30% of the company's stock.

DexCom Stock Down 0.2 %

Shares of DXCM traded down $0.13 during midday trading on Friday, hitting $70.35. The company had a trading volume of 2,734,043 shares, compared to its average volume of 3,907,564. The company's 50 day moving average price is $69.92 and its 200 day moving average price is $96.37. The stock has a market cap of $27.48 billion, a price-to-earnings ratio of 42.13, a PEG ratio of 2.20 and a beta of 1.18. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.